Diaceutics (DXRX.L)

Executive Summary

Diaceutics is a leading precision medicine commercialization company that leverages real-world data, diagnostic expertise, and physician engagement through its DXRX platform to ensure every patient receives the right therapy at the right time. Headquartered in Belfast, UK, and publicly traded (LSE: DXRX), the company helps pharmaceutical and biotech firms accelerate therapy adoption by integrating diagnostic insights into commercial strategies. In a rapidly evolving precision medicine landscape, Diaceutics is well-positioned to capitalize on the increasing demand for biomarker-driven therapies and personalized treatment approaches. The company's focus on end-to-end commercialization, from clinical trial support to market access, provides a unique value proposition that differentiates it from traditional contract research organizations and diagnostic providers.

Upcoming Catalysts (preview)

• Q3 2026Launch of Advanced AI Module for Biomarker Testing Insights75% success
• Q2 2026Major Pharmaceutical Partnership for Oncology Therapy Commercialization60% success
• Q1 2026Fiscal Year 2025 Earnings Release and Guidance Update90% success